Guiyu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guiyu Li has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Jianwei Liao
Department of Research and Development Shisenhai (Hangzhou) Pharmaceutical Technology Co., Ltd. Hangzhou Zhejiang China
1 shared publicationXingyuan Cao
Department of Veterinary Pharmacology and Toxicology College of Veterinary Medicine China Agricultural University Beijing China
1 shared publication- Yanming Wei
College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China
1 shared publication
Latest Publications
- Open Access
- 11 February 2023
- Published by Wiley in Veterinary Medicine and Science
- Vol. 9 (3) , 1211-1216
Pharmacokinetics of tenvermectin in swine, a novel antiparasitic drug candidate—comparison with ivermectin
Tenvermectin (TVM) is a novel 16‐membered macrolide compound isolated and purified from the fermentation broth of genetically engineered Streptomyces avermitilis strain MHJ1011. TVM and ivermectin were administered at the dose of 0.3 mg/kg body weight through a single subcutaneous injection route followed by plasma collectiom and analysis at different time intervals. Plasma concentrations of TVM and IVM were determined by high‐performance liquid chromatography with fluorescence detector. Pharmacokinetic analysis was completed using the non‐compartmental method with WinNonlin™ 6.4 software. TVM is rapidly absorbed after administration with peak plasma concentrations (Cmax, 9.78 ± 2.34 ng/ml) obtained within 6–22 h. AUC0‐last was 586.86 h·ng/ml ± 121.24 h·ng/ml. The mean elimination half‐life of TVM (T1/2λz) was 97.99 h ± 46.41 h. The T1/2λz of IVM was 146.59 h ± 22.26 h in the study. The present study showed that subcutaneous administration of TVM at 0.3 mg/kg body weight (BW) in swine is absorbed more rapidly than IVM in swine. Compared to the pharmacokinetic characteristics of IVM, there was little difference in the half‐life of TVM among different individuals. The data will contribute to refining the formulation and dosage regime for TVM administration.
- 11 February 2023
- Published by Wiley in Veterinary Medicine and Science
- Vol. 9 (3) , 1211-1216
Open AccessPharmacokinetics of tenvermectin in swine, a novel antiparasitic drug candidate—comparison with ivermectin
Tenvermectin (TVM) is a novel 16‐membered macrolide compound isolated and purified from the fermentation broth of genetically engineered Streptomyces avermitilis strain MHJ1011. TVM and ivermectin were administered at the dose of 0.3 mg/kg body weight through a single subcutaneous injection route followed by plasma collectiom and analysis at different time intervals. Plasma concentrations of TVM and IVM were determined by high‐performance liquid chromatography with fluorescence detector. Pharmacokinetic analysis was completed using the non‐compartmental method with WinNonlin™ 6.4 software. TVM is rapidly absorbed after administration with peak plasma concentrations (Cmax, 9.78 ± 2.34 ng/ml) obtained within 6–22 h. AUC0‐last was 586.86 h·ng/ml ± 121.24 h·ng/ml. The mean elimination half‐life of TVM (T1/2λz) was 97.99 h ± 46.41 h. The T1/2λz of IVM was 146.59 h ± 22.26 h in the study. The present study showed that subcutaneous administration of TVM at 0.3 mg/kg body weight (BW) in swine is absorbed more rapidly than IVM in swine. Compared to the pharmacokinetic characteristics of IVM, there was little difference in the half‐life of TVM among different individuals. The data will contribute to refining the formulation and dosage regime for TVM administration.